CAR T and Other Options for Relapsed/Refractory Follicular Lymphoma: Javier L. Munoz, MD, MS, FACP

Video

The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.

This content originally appeared on our sister site, CancerNetwork.

Related Videos
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Holly Peay, PhD, senior research scientist at RTI International
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
Holly Peay, PhD, senior research scientist at RTI International
Terence R. Flotte, MD, the vice president of ASGCT and the provost and executive deputy chancellor of UMass Chan Medical School
Deepak L. Bhatt, MD, MPH, MBA
Jeffrey Chamberlain, PhD, on Bringing Back the Focus to Basic Research for ASGCT 2024
Related Content
TDT/SCD Lentiviral Therapy Boasts Quick, Well-Tolerated Engraftment in Patients

TDT/SCD Lentiviral Therapy Boasts Quick, Well-Tolerated Engraftment in Patients

May 7th 2024
Article

KL003 favorably compares to platelet and neutrophil recovery rates of approved gene therapies.

David Jacobsohn, MD, MBA, chief, division of Blood and Marrow Transplantation, Children’s National,

First Patient Set to Receive bluebird’s Approved Sickle Cell Gene Therapy, Lyfgenia

May 7th 2024
Article

Lovo-cel was approved as Lyfgenia in December 2023.

Jennifer Gori, PhD, vice president of research at Prime Medicine

Prime Medicine’s Gene-Edited Stem Cell Product PM359 Cleared for US Trial in Chronic Granulomatous Disease

May 6th 2024
Article

The company anticipates that initial data from the study will be announced next year.

CGTLive®’s Weekly Rewind – April 26, 2024

CGTLive®’s Weekly Rewind – May 3, 2024

May 3rd 2024
Article

Review top news and interview highlights from the week ending May 3, 2024.

ODAC Supports MRD Endpoint in Accelerated Approval for Multiple Myeloma

ODAC Supports MRD Endpoint in Accelerated Approval for Multiple Myeloma

May 3rd 2024
Article

The ODAC unanimously voted in favor of the use of minimal residual disease negativity.

Brian Caveney, MD, Labcorp's president of Early Development Research Laboratories and chief medical and scientific officer

Labcorp’s Companion Diagnostic Assay for Beqvez Receives FDA Approval

May 2nd 2024
Article

Testing for the presence of neutralizing antibodies is an essential step before patients can receive Beqvez.

© 2024 MJH Life Sciences

All rights reserved.